Moderna COVID-19 Vaccine (mRNA-1273)

According to clinical trial evidence, the Moderna COVID-19 vaccine was 94.1 percent effective in preventing laboratory-confirmed COVID-19 infection in people ages 18 and older who received two doses and had no evidence of being previously infected in people who received two doses and had no evidence of being previously infected.

In clinical studies, the vaccination was also successful at preventing COVID-19 across patients of all ages, genders, races, and ethnicities, as well as those with underlying medical disorders.

Evidence suggests that mRNA COVID-19 vaccinations provide similar protection in real-world settings as they do in clinical trials, lowering the risk of COVID-19, including severe illness, by 90 percent or more among those who are fully vaccinated.

MORE INFORMATION:
Manufacturer: ModernaTX, Inc.
Number of Shots: 2 shots, 28 days apart
Moderately or severely immunocompromised people should get an additional primary shot (third dose) at least 28 days after their second shot.
Type of Vaccine: mRNA